Application of CRISPR-Cas9 for Long Noncoding RNA Genes in Cancer Research

Hum Gene Ther. 2019 Jan;30(1):3-9. doi: 10.1089/hum.2018.063. Epub 2018 Nov 20.

Abstract

Long noncoding RNAs (LncRNA), a class of transcripts with lengths >200 nt, play a master role in the regulation of cancer pathogenesis. Recently, the CRISPR-Cas9 system has been explored as a revolutionary genome editing tool for molecular biology. Growing evidence shows that LncRNAs can be targeted by the CRISPR-Cas9 system used for evaluating its function. Thus, the CRISPR-Cas9 systems provide a novel gene-editing strategy for the modification of LncRNA expression. This review summarizes current knowledge of the functions and underlying mechanisms of LncRNA by CRISPR-Cas9. Emerging strategies for non-viral/viral delivery of CRISPR-Cas9 in a clinical context are also discussed.

Keywords: CRISPR-Cas9; LncRNA; cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Biomarkers, Tumor
  • CRISPR-Cas Systems*
  • Cell Transformation, Neoplastic / genetics
  • Gene Editing*
  • Gene Expression Regulation, Neoplastic
  • Gene Regulatory Networks
  • Gene Transfer Techniques
  • Genetic Therapy
  • Humans
  • Neoplasms / genetics*
  • Neoplasms / pathology
  • Neoplasms / therapy
  • RNA Interference
  • RNA, Long Noncoding / chemistry
  • RNA, Long Noncoding / genetics*
  • Research

Substances

  • Biomarkers, Tumor
  • RNA, Long Noncoding